Phase 1 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with advanced clear cell kidney cancer (confirmed through a tissue sample test)
• People whose kidney cancer has continued to grow or spread on imaging scans after being treated with a type of immunotherapy called a checkpoint inhibitor — either during or after treatment in the first-line (initial) setting, or within 6 months after finishing adjuvant (preventive post-surgery) immunotherapy
• People who have received at least two previous treatment courses for their cancer (there is no upper limit on how many prior treatments)
• People who have measurable tumours visible on imaging scans, based on standard measurement guidelines
• People who have recovered from side effects of previous cancer treatments to near their original health levels, unless any remaining side effects are considered minor and stable by the treating doctor
• People aged 18 and over
• People with a Karnofsky performance score of 60% or higher, which is a medical measure of how well a person can carry out daily activities (confirm with trial site)
• People whose blood counts, liver function, and kidney function meet specific minimum levels set by the trial — some flexibility may be allowed if results outside the range are not considered clinically significant by the lead investigator, and reference ranges may account for variations related to race, ethnicity, age, sex, or gender identity
• People living with HIV who are on effective treatment and have had an undetectable amount of virus in their blood within the past 6 months
• People with chronic hepatitis B who have an undetectable viral load while on appropriate suppressive therapy
• People with a history of hepatitis C who have been successfully treated and cured, or who are currently being treated and have an undetectable hepatitis C viral load
• People who have had brain tumours (spread from the kidney cancer) that have already been treated, where follow-up brain scans show the cancer has not continued to grow
• People with new or worsening brain tumours or cancer spread to the lining of the brain, if the treating doctor determines that urgent brain-specific treatment is not needed right away or is unlikely to be needed in the first treatment cycle
• People who have or have had another cancer, as long as that cancer or its treatment is not expected to interfere with the safety or results of this trial
• People with a known history of heart disease or prior treatment with heart-affecting medications, provided a heart function assessment places them at Class 2B or better using a standard heart classification system (confirm with trial site)
• People who agree to use an adequate method of contraception throughout the study, beginning from the time of the first study imaging agent dose
• People who are willing and able to understand and sign a written consent form

Who may not be able to join:

• People who have not recovered from side effects of previous cancer treatment (side effects still rated above a mild level), except for hair loss
• People currently taking part in another clinical trial involving an experimental treatment
• People who have had a serious allergic reaction to a drug with a similar makeup to girentuximab (the imaging agent used in this trial)
• People with another illness that is not well controlled, as determined by the investigator
• People who are pregnant, as one of the trial drugs (belzutifan) carries a risk of harming an unborn baby

Important: Always verify eligibility with the trial site directly before applying.